Paul J Sekhri
CIK 1264519 · Pres, CEO and Exec Chairperson · last filed 2026-09-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VEEV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4280 HACIENDA DRIVE
PLEASANTON, CA 94588
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VEEV | Director | 15,651 | $306.40 | $4.80M | -$8.39M | 72 | 2026-09-03 |
| APMD | Director | 12,500 | $15.81 | $197.6K | $200.0K | 1 | 2026-08-03 |
| VTVT | Pres, CEO and Exec Chairperson | 5,000 | $21.18 | $105.9K | $83.8K | 4 | 2026-02-18 |
| Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Director | — | $59.98 | — | $0 | 4 | 2024-12-02 |
| Axcella Health Inc. (AXLA) Delisted | Director | — | $0.40 | — | $0 | 1 | 2022-05-25 |
| BiomX Inc. (PHGE.WS) Delisted | Director | 12,500 | $0.01 | $110 | $50.0K | 3 | 2021-07-30 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | — | $64.97 | — | $0 | 3 | 2020-01-06 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Director | — | — | — | $0 | 1 | 2016-09-14 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | — | — | — | $0 | 3 | 2010-05-03 |
Recent Filings · Page 4 of 10
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-20 | VEEV | Gift (G) | −702 | $0 | EDGAR |
| 2022-12-05 | VEEV | Exer (M) | +313 | $0 | EDGAR |
| 2022-09-06 | VEEV | Exer (M) | +313 | $0 | EDGAR |
| 2022-06-13 | VEEV | Grant (A) | — | $0 | EDGAR |
| 2022-06-02 | VEEV | Exer (M) | +189 | $0 | EDGAR |
| 2022-05-31 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-25 | Axcella Health Inc. (AXLA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-04-01 | VEEV | Sell (S) | −11,000 | -$2.35M | EDGAR |
| 2022-03-03 | VEEV | Exer (M) | +189 | $0 | EDGAR |
| 2021-12-03 | VEEV | Exer (M) | +189 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.